share_log

HCA Healthcare | 10-Q: Q2 2024 Earnings Report

HCA Healthcare | 10-Q: Q2 2024 Earnings Report

HCA医疗 | 10-Q:2024财年二季报
美股SEC公告 ·  2024/07/30 04:35

Moomoo AI 已提取核心信息

HCA Healthcare reported strong Q2 2024 financial results with revenues increasing 10.3% to $17.49 billion, driven by a 6.0% rise in admissions and a 4.1% growth in revenue per equivalent admission. Net income attributable to HCA Healthcare grew 22.5% to $1.46 billion, or $5.53 per diluted share, compared to $1.19 billion in Q2 2023. The quarter included $12 million in gains from facility sales.Operating metrics showed robust growth with same-facility admissions up 5.8% and emergency room visits increasing 5.3%. Labor costs improved as contract labor expenses declined 25.7% year-over-year, while salaries and benefits as a percentage of revenues decreased to 43.9% from 45.9%. The company maintained strong cost management with supplies at 15.1% of revenues, down from 15.6% in the prior year.During the quarter, HCA continued its capital deployment strategy, repurchasing 4.2 million shares at an average price of $324.16 per share. The company issued $4.5 billion in senior notes in February 2024 and repaid $2.0 billion in maturing notes in March. Operating cash flow remained healthy at $1.97 billion for Q2, though down from $2.48 billion in Q2 2023 primarily due to working capital changes.
HCA Healthcare reported strong Q2 2024 financial results with revenues increasing 10.3% to $17.49 billion, driven by a 6.0% rise in admissions and a 4.1% growth in revenue per equivalent admission. Net income attributable to HCA Healthcare grew 22.5% to $1.46 billion, or $5.53 per diluted share, compared to $1.19 billion in Q2 2023. The quarter included $12 million in gains from facility sales.Operating metrics showed robust growth with same-facility admissions up 5.8% and emergency room visits increasing 5.3%. Labor costs improved as contract labor expenses declined 25.7% year-over-year, while salaries and benefits as a percentage of revenues decreased to 43.9% from 45.9%. The company maintained strong cost management with supplies at 15.1% of revenues, down from 15.6% in the prior year.During the quarter, HCA continued its capital deployment strategy, repurchasing 4.2 million shares at an average price of $324.16 per share. The company issued $4.5 billion in senior notes in February 2024 and repaid $2.0 billion in maturing notes in March. Operating cash flow remained healthy at $1.97 billion for Q2, though down from $2.48 billion in Q2 2023 primarily due to working capital changes.
HCA医疗报告了2024年第二季度强劲的财务业绩,营业收入增长了10.3%,达到了174.9亿美金,这得益于入院人数上涨了6.0%以及每个等效入院收入增长了4.1%。归属于HCA医疗的净利润增长了22.5%,达到14.6亿美金,或每股5.53美金,而2023年第二季度为11.9亿美金。本季度包括1200万美金的设施销售收益。运营指标显示出强劲的增长, 同一设施的入院人数上升了5.8%,急诊室就诊人数增加了5.3%。劳动成本有所改善,合同劳动力费用同比下降了25.7%,而薪资和福利占营业收入的比例从45.9%下降至43.9%。公司保持了强有力的成本管理,供应品占营业收入的比例为15.1%,低于去...展开全部
HCA医疗报告了2024年第二季度强劲的财务业绩,营业收入增长了10.3%,达到了174.9亿美金,这得益于入院人数上涨了6.0%以及每个等效入院收入增长了4.1%。归属于HCA医疗的净利润增长了22.5%,达到14.6亿美金,或每股5.53美金,而2023年第二季度为11.9亿美金。本季度包括1200万美金的设施销售收益。运营指标显示出强劲的增长, 同一设施的入院人数上升了5.8%,急诊室就诊人数增加了5.3%。劳动成本有所改善,合同劳动力费用同比下降了25.7%,而薪资和福利占营业收入的比例从45.9%下降至43.9%。公司保持了强有力的成本管理,供应品占营业收入的比例为15.1%,低于去年的15.6%。在本季度,HCA继续其资本部署策略,以每股324.16美金的平均价格回购了420万股。公司在2024年2月发行了45亿美金的高级票据,并在3月偿还了20亿美金到期的票据。运营现金流保持健康,2024年第二季度为19.7亿美金,尽管低于2023年第二季度的24.8亿美金,主要由于营运资本的变动。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息